Is MAIA Biotechnology Stock a Good Investment?
MAIA Biotechnology Investment Advice | MAIA |
- Examine MAIA Biotechnology's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MAIA Biotechnology's leadership team and their track record. Good management can help MAIA Biotechnology navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MAIA Biotechnology's business and its evolving consumer preferences.
- Compare MAIA Biotechnology's performance and market position to its competitors. Analyze how MAIA Biotechnology is positioned in terms of product offerings, innovation, and market share.
- Check if MAIA Biotechnology pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MAIA Biotechnology's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MAIA Biotechnology stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MAIA Biotechnology is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves slightly opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine MAIA Biotechnology Stock
Researching MAIA Biotechnology's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 17.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.34. MAIA Biotechnology had not issued any dividends in recent years.
To determine if MAIA Biotechnology is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MAIA Biotechnology's research are outlined below:
| MAIA Biotechnology generated a negative expected return over the last 90 days | |
| MAIA Biotechnology has high historical volatility and very poor performance | |
| MAIA Biotechnology has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (19.77 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MAIA Biotechnology currently holds about 8.15 M in cash with (13.07 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.75. | |
| Roughly 17.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Analysts Set Expectations for MAIA Biotechnology Q1 Earnings - MarketBeat |
MAIA Biotechnology uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MAIA Biotechnology. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MAIA Biotechnology's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact MAIA Biotechnology's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises MAIA Biotechnology's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.39 | -0.46 | -0.07 | 17 | ||
2024-11-14 | 2024-09-30 | -0.47 | -0.11 | 0.36 | 76 |
MAIA Biotechnology's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 54.46 M.Market Cap |
|
MAIA Biotechnology's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.61) | (2.74) | |
| Return On Capital Employed | (7.67) | (7.29) | |
| Return On Assets | (2.61) | (2.74) | |
| Return On Equity | (41.41) | (39.34) |
Determining MAIA Biotechnology's profitability involves analyzing its financial statements and using various financial metrics to determine if MAIA Biotechnology is a good buy. For example, gross profit margin measures MAIA Biotechnology's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MAIA Biotechnology's profitability and make more informed investment decisions.
Please note, the presentation of MAIA Biotechnology's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, MAIA Biotechnology's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of MAIA Biotechnology's management manipulating its earnings.
Evaluate MAIA Biotechnology's management efficiency
MAIA Biotechnology has return on total asset (ROA) of (1.0711) % which means that it has lost $1.0711 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (5.5956) %, meaning that it created substantial loss on money invested by shareholders. MAIA Biotechnology's management efficiency ratios could be used to measure how well MAIA Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -2.74. The current year's Return On Capital Employed is expected to grow to -7.29. At present, MAIA Biotechnology's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.59, whereas Total Assets are forecasted to decline to about 7.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.04 | 0.03 | |
| Tangible Book Value Per Share | 0.04 | 0.03 | |
| Enterprise Value Over EBITDA | (0.41) | (0.39) | |
| Price Book Value Ratio | 32.49 | 34.12 | |
| Enterprise Value Multiple | (0.41) | (0.39) | |
| Price Fair Value | 32.49 | 34.12 | |
| Enterprise Value | 8.4 M | 7.9 M |
The operational strategies employed by MAIA Biotechnology management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Beta 0.34 |
Basic technical analysis of MAIA Stock
As of the 22nd of November, MAIA Biotechnology secures the Standard Deviation of 5.09, market risk adjusted performance of (0.43), and Mean Deviation of 3.87. Compared to fundamental indicators, the technical analysis model lets you check possible technical drivers of MAIA Biotechnology, as well as the relationship between them.MAIA Biotechnology's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MAIA Biotechnology insiders, such as employees or executives, is commonly permitted as long as it does not rely on MAIA Biotechnology's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MAIA Biotechnology insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand MAIA Biotechnology's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MAIA Biotechnology's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 3.87 | |||
| Coefficient Of Variation | (1,475) | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.94 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 28.1 | |||
| Value At Risk | (9.23) | |||
| Potential Upside | 8.37 | |||
| Skewness | 0.2462 | |||
| Kurtosis | 0.8674 |
| Risk Adjusted Performance | (0.04) | |||
| Market Risk Adjusted Performance | (0.43) | |||
| Mean Deviation | 3.87 | |||
| Coefficient Of Variation | (1,475) | |||
| Standard Deviation | 5.09 | |||
| Variance | 25.94 | |||
| Information Ratio | (0.09) | |||
| Jensen Alpha | (0.44) | |||
| Total Risk Alpha | (1.02) | |||
| Treynor Ratio | (0.44) | |||
| Maximum Drawdown | 28.1 | |||
| Value At Risk | (9.23) | |||
| Potential Upside | 8.37 | |||
| Skewness | 0.2462 | |||
| Kurtosis | 0.8674 |
Consider MAIA Biotechnology's intraday indicators
MAIA Biotechnology intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MAIA Biotechnology stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 4546.01 | |||
| Daily Balance Of Power | (0.50) | |||
| Rate Of Daily Change | 0.97 | |||
| Day Median Price | 2.14 | |||
| Day Typical Price | 2.12 | |||
| Price Action Indicator | (0.1) | |||
| Period Momentum Indicator | (0.07) |
MAIA Biotechnology Corporate Filings
| 12th of November 2024 Other Reports | ViewVerify | |
8K | 8th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 25th of October 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
MAIA Stock media impact
Far too much social signal, news, headlines, and media speculation about MAIA Biotechnology that are available to investors today. That information is available publicly through MAIA media outlets and privately through word of mouth or via MAIA internal channels. However, regardless of the origin, that massive amount of MAIA data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MAIA Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MAIA Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MAIA Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MAIA Biotechnology alpha.
MAIA Biotechnology Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MAIA Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MAIA Biotechnology Corporate Management
| MD MBA | President, CoFounder | Profile | |
| Joseph McGuire | Chief Officer | Profile | |
| Sergei Gryaznov | Chief Officer | Profile | |
| Jeffrey Himmelreich | Head Finance | Profile | |
| Mihail MD | Chief Devel | Profile | |
| Linda Moreira | Company Secretary | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MAIA Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For information on how to trade MAIA Stock refer to our How to Trade MAIA Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MAIA Biotechnology. If investors know MAIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MAIA Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.34) | Return On Assets (1.07) | Return On Equity (5.60) |
The market value of MAIA Biotechnology is measured differently than its book value, which is the value of MAIA that is recorded on the company's balance sheet. Investors also form their own opinion of MAIA Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is MAIA Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MAIA Biotechnology's market value can be influenced by many factors that don't directly affect MAIA Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between MAIA Biotechnology's value and its price, as these two are different measures arrived at by various means. Investors typically determine if MAIA Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MAIA Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.